Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 11/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28934426 | 1.00 | PIK3CD (0.46) | PIK3CDCHEK2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL29131921 | 0.90 | PIK3CD (0.42) | PIK3CDCHEK2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL29131923 | 0.90 | PIK3CD (0.42) | PIK3CDCHEK2PIK3CAPIK3CBPIK3CG | |
| SCHEMBL28963149 | 0.88 | HCRTR1 (0.43) | PIK3CDHCRTR1HCRTR2PBRM1 | |
| SCHEMBL28963147 | 0.88 | HCRTR1 (0.43) | PIK3CDHCRTR1HCRTR2PBRM1 | |
| SCHEMBL24840287 | 0.83 | NLRP3 (0.52) | HCRTR1HCRTR2PBRM1 | |
| SCHEMBL30108771 | 0.83 | NLRP3 (0.52) | HCRTR1HCRTR2PBRM1 | |
| SCHEMBL30168040 | 0.83 | NLRP3 (0.52) | HCRTR1HCRTR2PBRM1 | |
| SCHEMBL28934400 | 0.83 | NLRP3 (0.52) | HCRTR1HCRTR2PBRM1 | |
| SCHEMBL31091178 | 0.83 | PRMT5 (0.42) | PIK3CDPRMT5USP30SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2024-09-05 | — | — | US | disclosed |
| CN-115433163-A | NLRP3 inflammasome inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294542-A1 | NLRP3 INFLAMMASOME INHIBITOR AND APPLICATION THEREOF | NLRP3, NLRP1, PYCARD | PIK3CD 3309/4885CHEK2 4243/4885PIK3CA 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.